⁉️What on earth is Lp (a) and why does it matter⁉️
Need a primer this mysterious little molecule❓
Look no further than my first ever @CardioNerds InfoGraphic below 👇
Applications for the next cohort of the @CardioNerds Academy are due April 28th!
🌟 Revised curriculum tailored to the evolving landscape of digital MedEd
🌟 Develop skills in scientific writing, visual graphic creation, & podcast development
🔗https://t.co/K1ICGwpnUq
In @JAMACardio, we compare cardiovascular hospitalization rates in the US 🇺🇸 to another high-income country w/ a universal health system - Denmark 🇩🇰
CV hospitalizations were 1.5X ⬆️ US vs Denmark, driven by MI & HF. Income-based gaps also greater in 🇺🇸
https://t.co/JKDpk63gQj
1/20: 50 y/o M with HTN & a family history of premature CAD presents to discuss the results of his labs. His Lp(a) is 200 nmol/L. His 10-year ASCVD risk based on the pooled cohort equation is 9.1%. What does his elevated Lp(a) level signify? How should your management change?
Check out some of the work from our group at #AHA24@AHAScience
Saturday
🔸Lipoprotein a and outcomes after coronary angiography (early career award finalist)
@KelvinS_MD@CFAndersenMD with @mchonig
🔸An integrated germline and somatic genomic model improves risk prediction for coronary artery disease
@MinSeoKim_MD Xiong Yang with @pnatarajanmd and @wallacemwang
🔸Characterization of cardiac allograft vasculopathy on serial coronary angiography of heart transplant patients
Brian Huang with @GLewisCardiol
🔸Integrating clinical, genetic, and electrocardiographic-based artificial intelligence to estimate risk of incident atrial fibrillation
@ShinoKany with @shaan_khurshid and @patrick_ellinor
Sunday
🔸Quantifying the burden of high polygenic risk for cardiometabolic disease in a US-based healthcare system biobank
Anika Misra with @AniruddhPatelMD and @pnatarajanmd
🔸Comparative performance of PREVENT and Pooled Cohort Equations to predict cardiovascular disease in multisite healthcare populations
@somijemmacho with @pnatarajanmd
Monday
🔸Diagnostic yield and testing of an invasive coronary function testing program
Fouad Bitar
@mghcvrc@broadinstitute@MGHHeartHealth@mghmedres
Two important implications of this NHANES-based paper from @ShoaClarke@blakewthomson@StanfordMed. For younger adults (20-39yo), (1) current risk prediction is woefully insufficient, and (2) when elevated risk is recognized, there needs to be markedly better implementation of statins https://t.co/Qx677piemk
Another outcomes trial win for GLP-1 medicines now with Semaglutide and the ESSENCE trial in metabolic liver disease with reduction in both inflammation and fibrosis #MASH https://t.co/EE8jGRnU9s
Super proud of this work comparing plaque burden assessment by CCTA and CAC scoring. Big thanks to an all-star team of imaging experts for their mentorship and guidance! @RAQuintMD@TiffanyDong6@MichaelJBlaha@lesleejshaw